Last update 21 Nov 2024

Rocakinogene Sifuplasmid

Overview

Basic Info

Drug Type
Personalized antigen vaccine, Therapeutic vaccine
Synonyms
Rocakinogene Sifuplasmid
Target-
Mechanism
Immunostimulants
Originator Organization
Active Organization
Inactive Organization
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Locally Advanced Urothelial CarcinomaPhase 2
US
24 May 2018
Uterine Cervical CancerPhase 2--
Transitional Cell CarcinomaDiscovery
US
24 May 2018
Transitional Cell CarcinomaDiscovery
ES
24 May 2018
Head and Neck NeoplasmsDiscovery
US
26 Jun 2017
Human Papillomavirus InfectionDiscovery
US
26 Jun 2017
Human Papillomavirus InfectionDiscovery
US
26 Jun 2017
Squamous Intraepithelial Lesions of the CervixDiscovery
US
26 Jun 2017
Urogenital AbnormalitiesDiscovery
US
26 Jun 2017
Vulvar DiseasesDiscovery
US
26 Jun 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
56
CELLECTRA® 2000
(Cohort A - Arm 1)
wrbaxdqxnz(nrotodrehn) = dlvmzkmhbb jbpjuznpxp (rufhpldmgt, aefxmcyvsi - hlmlmlbvsb)
-
31 May 2023
CELLECTRA® 2000+INO-9012+PENNVAX-GP
(Cohort A - Arm 2)
wrbaxdqxnz(nrotodrehn) = gmvciopefj jbpjuznpxp (rufhpldmgt, lpxefsqthx - nftuutdauf)
Phase 1/2
24
(twevndlxsd) = llgloxifrg sljggpengp (keasiwcswf )
Positive
01 Nov 2022
Phase 1/2
Glioblastoma
First line
52
electroporation+cemiplimab+Temozolomide+Radiation Therapy+INO-5401+INO-9012
(unmethylated MGMT)
(wsjgbmugqt) = xtxvlqyrde zzsnguooiq (ibprzhsyao, 14.5 - 19.8)
Positive
02 Jun 2022
electroporation+cemiplimab+Temozolomide+Radiation Therapy+INO-5401+INO-9012
(methylated MGMT)
(wsjgbmugqt) = rbcuhbiwxx zzsnguooiq (ibprzhsyao, 18.4 - NR)
Phase 1/2
24
INO-9012+pembrolizumab+GNOS-PV02
(jarurnyopu) = oxawnmxefz gnyzfxckrn (jgjndutgph )
Positive
11 Nov 2021
Phase 1/2
-
GNOS-PV02 + INO-9012 + Pembrolizumab
gtiyejuqsv(iqsjjlgxdv) = ovjerhtvlp pokqibownj (erfnvutzbu )
Positive
10 Nov 2021
Phase 1/2
Glioblastoma
First line
52
(Cohort A:32 pts,MGMT unmethylated;Cohort B:20 pts,MGMT methylated)
(rrhpleorqh) = 1/69 related to the combination therapy, Grade 1 pyrexia. elouacxzfo (xlyvhkutqp )
Positive
29 May 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free